Peginterferon alfa-2b
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Peginterferon alfa-2b?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Pegylated interferon alfa-2b is a drug used to treat melanoma, as an adjuvant therapy to surgery.[3] Also used to treat hepatitis C (typically, in combination with ribavarin), it is no longer recommended due to poor efficacy and adverse side-effects.[4] Subcutaneous injection is the preferred delivery method.[3]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | PegIntron, Sylatron, ViraferonPeg, others |
AHFS/Drugs.com | Professional Drug Facts |
MedlinePlus | a605030 |
Routes of administration | Subcutaneous injection |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Elimination half-life | 22–60 hrs |
Identifiers | |
| |
CAS Number | |
IUPHAR/BPS | |
DrugBank |
|
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
ECHA InfoCard | 100.208.164 |
Chemical and physical data | |
Formula | C860H1353N229O255S9 |
Molar mass | 19269.17 g·mol−1 |
NY (what is this?) (verify) |
Close
Belonging to the alpha interferon family of medications, the molecule is PEGylated to prevent breakdown.[3][4] Approval for medical use in the United States was granted in 2001.[3] It is on the World Health Organization's List of Essential Medicines as a therapy for chronic hepatitis C.[5][6]